Side-by-side · Research reference

TB-500vsTirzepatide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2Reviewed8/46 cited

BFDA-ApprovedVerified14/45 cited

TB-500

Thymosin β4 fragment · Healing

2 mgPer doseGoldstein 2012

Phase 2Evidence levelGoldstein 2012

~2 hrHalf-life

SQ or IM · Multiple sites · 2–3×/week

Tirzepatide

GIP+GLP-1 Dual Agonist · FDA-Approved

2.5–15 mgWeekly doseZEPBOUND (tirzepatide) injecti 2023

20.9%Body-weight ↓Jastreboff 2022

~5 daysHalf-lifeZEPBOUND (tirzepatide) injecti 2023

SQ · Abdomen / thigh / arm · Once weekly

01Mechanism of Action

Parameter

TB-500

Tirzepatide

Primary target

G-actin (sequestering) + cell-surface integrinsGoldstein 2012

GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018

Pathway

Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012 Malinda 1999

Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022 Frias 2018

Downstream effect

Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012

Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022

Feedback intact?

Endogenous protein at baseline; supplementation amplifies

Glucose-dependent insulin release preserves physiological feedback

Origin

17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012

39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018

Antibody development

—

02Dosage Protocols

Parameter

TB-500

Tirzepatide

Standard dose

2 mg per injectionGoldstein 2012

Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.

—

Frequency

2× per week (loading); then 1× per week (maintenance)

—

Lower / starter dose

1 mg per injection

—

Evidence basis

Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012

FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022 ZEPBOUND (tirzepatide) injecti 2023

Duration

4–8 weeks loading; longer maintenance for chronic injury

Indefinite for chronic indication

Reconstitution

Bacteriostatic water, 1–2 mL per 5 mg vial

Pre-filled commercial pen. Research vial: bacteriostatic water per label.

Timing

Evening or pre-rest preferred (anecdotal)

Once weekly, any time of day

Half-life

~2 hours (estimated; tissue uptake longer)

~5 days (116 h)ZEPBOUND (tirzepatide) injecti 2023

Standard dose (T2D)

—

5–15 mg / weekZEPBOUND (tirzepatide) injecti 2023

Standard dose (weight)

—

5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023 Jastreboff 2022

Titration schedule

—

2.5 mg → +2.5 mg every 4 weeks → 15 mg max

Slower titration mitigates GI side effects.

04Side Effects & Safety

Parameter

TB-500

Tirzepatide

Injection site reaction

Mild erythema, transient pain

Mild erythema, pruritus

GI symptoms

Rare nausea (anecdotal)

Nausea, vomiting, diarrhea (common, dose-dependent)Jastreboff 2022

Cancer risk

Theoretical via angiogenesis pathway

—

Lethargy / fatigue

Reported anecdotally during loading phase

—

Antibody formation

No data (no long-term human trials)

—

Pregnancy / OB

Avoid

Contraindicated

Long-term safety

Unknown beyond Phase 2

—

Pancreatitis risk

—

Rare; discontinue if suspectedZEPBOUND (tirzepatide) injecti 2023

Thyroid C-cell tumours

—

Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023

Hypoglycemia

—

Low as monotherapy; risk with sulfonylureas / insulin

Gallbladder events

—

Increased cholelithiasis

Diabetic retinopathy

—

Rapid glycemic improvement may transiently worsen

Absolute Contraindications

TB-500

·Active malignancy (theoretical angiogenesis concern)
·Pregnancy / breastfeeding

Tirzepatide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to tirzepatide

Relative Contraindications

TB-500

·Cancer history
·Concurrent VEGF inhibitor therapy

Tirzepatide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy

05Administration Protocol

Parameter

TB-500

Tirzepatide

1. Reconstitution

Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.

Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.

2. Injection site

SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.

SQ — abdomen, thigh, or upper arm. Rotate weekly.

3. Timing

Evening or pre-sleep is most common anecdotal timing.

Once weekly, same day. Day change allowed if ≥3 days separate doses.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.

5. Needle

27–31G, 4–8 mm insulin syringe.

Pen-supplied. Research vial: 27–31G insulin syringe.

06Stack Synergy

TB-500

+ BPC-157

Strong

View BPC-157 →

TB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.

TB-500: 2 mg SQ · 2× per week
BPC-157: 250–500 mcg SQ · daily
Primary benefit: Combined angiogenesis + cell migration for tendon/ligament/muscle repair

Tirzepatide

— no documented stacks